Jamieson is delighted to announce that it has advised the management team of LGC on KKR’s sale of the business to Cinven and Astorg.
LGC is one of the largest private Life Science Tools companies in the world, providing tools for quality assurance and genomics applications in a range of sectors, including human healthcare and applied markets. The company is headquartered in London and has over 3,200 employees with operations across 22 countries.
The Jamieson team, led by Stuart Coventry and Andrew Cox, advised Tim Robinson (CEO) and his team on their reinvestment alongside the acquiring consortium, as well as the terms of the equity incentive programme to be implemented in the new holding structure.
Jamieson previously advised the team on KKR’s acquisition of the business from Bridgepoint in 2016.
